Sharemaestro company-news research for Marksans Pharma Limited (MARKSANS), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NSI India Provisional evidence

Company news sentiment

Latest MARKSANS news and sentiment

Marksans Pharma Limited

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research RSS feed
30-day score51Neutral is 50
Early balanced news score 19/100 evidence confidence 100% direct company focus 19 current stories across 10 publishers
Latest weekly closeINR 329.55week of 28 Aug 2026
Main news subjectEarnings79/100 share of current news
News data statusPartial23 duplicate stories removed

Current company news

Early balanced news score

19 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone61/100 Published 30-day score51/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline Marksans Pharma Ltd Technical Momentum Shifts to Bullish Amid Strong Monthly Gains MarketsMojo · 26 Aug 2026 18:49

What supports the score

Direct evidence

19 current stories are mapped specifically to MARKSANS.

Source breadth

The score uses 10 publishers rather than depending on one outlet.

What limits the score

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.114.

Confidence

Confidence is 19/100, below the threshold for a firm score.

51/100
News scoreEarly balanced news score
19/100
Confidencethin evidence
100%/100
Company news19 company stories
79/100
Story agreement21/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
06 Aug: 1 stories12 Aug: 8 stories13 Aug: 3 stories15 Aug: 1 stories16 Aug: 1 stories23 Aug: 1 stories25 Aug: 1 stories26 Aug: 1 stories 06 Aug: tone 50, 1 stories12 Aug: tone 74, 8 stories13 Aug: tone 32, 3 stories15 Aug: tone 75, 1 stories16 Aug: tone 50, 1 stories23 Aug: tone 50, 1 stories25 Aug: tone 50, 1 stories26 Aug: tone 69, 1 stories 95505
06 Aug21 Aug04 Sep
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence2
0.114 after freshness weighting
Source breadth100
10 independent publishers
Company relevance100
share tied directly to this company
Freshness6
recency-weighted evidence
Agreement79
how closely stories agree
Publisher mix82
less reliance on one publisher

Price and news history

Weekly price and news-score history

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

26 completed price weeks10 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
06 Mar 2026: close 171.050003, indexed 100.013 Mar 2026: close 167.009995, indexed 97.620 Mar 2026: close 170.050003, indexed 99.427 Mar 2026: close 163.080002, indexed 95.303 Apr 2026: close 168.149994, indexed 98.310 Apr 2026: close 178.479996, indexed 104.317 Apr 2026: close 179.229996, indexed 104.824 Apr 2026: close 190.210007, indexed 111.201 May 2026: close 184.630005, indexed 107.908 May 2026: close 197.759995, indexed 115.615 May 2026: close 207.449997, indexed 121.322 May 2026: close 211.860001, indexed 123.929 May 2026: close 246.190002, indexed 143.905 Jun 2026: close 233.190002, indexed 136.312 Jun 2026: close 252.369995, indexed 147.519 Jun 2026: close 259.670013, indexed 151.826 Jun 2026: close 256.070007, indexed 149.703 Jul 2026: close 264.450012, indexed 154.610 Jul 2026: close 272.399994, indexed 159.317 Jul 2026: close 266.364868, indexed 155.724 Jul 2026: close 245.622116, indexed 143.631 Jul 2026: close 257.638947, indexed 150.607 Aug 2026: close 273.096283, indexed 159.714 Aug 2026: close 332.083496, indexed 194.121 Aug 2026: close 321.299988, indexed 187.828 Aug 2026: close 329.549988, indexed 192.7 26 Jun 2026: news score 50, close 256.070007, 1 stories5003 Jul 2026: news score 52, close 264.450012, 2 stories10 Jul 2026: news score 51, close 272.399994, 6 stories5117 Jul 2026: news score 52, close 266.364868, 8 stories24 Jul 2026: news score 51, close 245.622116, 10 stories5131 Jul 2026: news score 54, close 257.638947, 13 stories07 Aug 2026: news score 52, close 273.096283, 12 stories5214 Aug 2026: news score 56, close 332.083496, 22 stories21 Aug 2026: news score 54, close 321.299988, 20 stories5428 Aug 2026: news score 53, close 329.549988, 22 stories53 Price index 206.0 144.7 83.5 News score 100 50 0
06 Mar02 Jun28 Aug
Weekly close, indexedSentiment score
26-week price+92.7%latest close 329.55
News score change+3first to latest comparable week
One-week response+2.6%Price confirming higher
Fair-value position+61.2%Materially above fair value
WeekNews scoreCloseWeekly move
28 Aug 202653INR 329.549988+2.6%
21 Aug 202654INR 321.299988-3.2%
14 Aug 202656INR 332.083496+21.6%
07 Aug 202652INR 273.096283+6.0%
31 Jul 202654INR 257.638947+4.9%
24 Jul 202651INR 245.622116-7.8%
17 Jul 202652INR 266.364868-2.2%
10 Jul 202651INR 272.399994+3.0%
Provisional evidence

News subjects

What is shaping the score

Earnings
Market update669 stories · 47%
Earnings579 stories · 47%
Analyst action751 stories · 5%

Source mix

Where the evidence comes from

82/100 independence
scanx.trade645 stories · 26%
simplywall.st742 stories · 11%
Investing.com302 stories · 11%
NDTV Profit622 stories · 11%
CNBC TV18811 stories · 5%
Equitypandit731 stories · 5%
MarketsMojo691 stories · 5%

Recurring subjects

Subjects appearing most often

Current evidence

Topic structure will appear when classified tags are present in the current feed.

Earlier readings

How the score has changed

26 comparable readings · 74 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+150 to 51 · Broadly stable
Observed range50–6350 is the neutral baseline
Evidence depth17stories at latest stored reading · +16
Confidence17/100Provisional · +17
22 Jun50 neutral04 Sep 23:53
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
04 Sep 23:5351-317/100 (-10)17 (-6)Provisional
26 Aug 23:5954+127/100 (+4)23 (+1)Provisional
25 Aug 23:5953+023/100 (-3)22 (+1)Provisional
23 Aug 23:5953-426/100 (-14)21 (-2)Provisional
16 Aug 23:5957+040/100 (-4)23 (0)Measured
15 Aug 23:5957+044/100 (-5)23 (0)Measured
13 Aug 23:5957-649/100 (+1)23 (+3)Measured
12 Aug 23:5963+1148/100 (+26)20 (+7)Measured

Source headlines

The news behind the score

Showing 1-19 of 19

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#169Tone
MarketsMojoDirect company coverageScored from headline

Marksans Pharma Ltd Technical Momentum Shifts to Bullish Amid Strong Monthly Gains

Published
26 Aug 2026 18:49
News subject
Market update
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 44/100
30-day weight
8.1% of the score · 7.2d old
Duplicates
1 consolidated
#3—Not directional
scanx.tradeDirect company coverageScored from headline

Marksans Pharma to acquire German firm ABCnow GmbH for €892,384

Published
23 Aug 2026 09:06
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 10.6d old
Duplicates
1 consolidated
#4—Not directional
simplywall.stDirect company coverageScored from headline

Marksans Pharma Limited (NSE:MARKSANS) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Published
16 Aug 2026 07:00
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 17.7d old
Duplicates
1 consolidated
#628Tone
Investing.comDirect company coverageScored from headline

Marksans Pharma Q1 FY27 slides: record profit, Europe surge despite miss

Published
13 Aug 2026 12:46
News subject
Earnings
Why this score
Missed expectations
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 51/100
30-day weight
15% of the score · 20.4d old
Duplicates
1 consolidated
#8—Not directional
UnivestDirect company coverageScored from headline

Marksans Pharma Q1 FY27 Results: Revenue Rs 840 Cr, PAT Rs 159 Cr and Key Highlights

Published
13 Aug 2026 07:00
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 20.7d old
Duplicates
1 consolidated
#966Tone
scanx.tradeDirect company coverageScored from headline

Marksans Pharma Q1 Results: Net profit rises 174% YoY to ₹1,594 crore

Published
12 Aug 2026 12:44
News subject
Earnings
Why this score
Operating growth
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 42/100
30-day weight
7.6% of the score · 21.4d old
Duplicates
1 consolidated
#1080Tone
NDTV ProfitDirect company coverageScored from headline

Marksans Pharma Stock Jumps 11% After Net Profit Jumps 2.5x, Revenue Surges 36%

Published
12 Aug 2026 07:29
News subject
Earnings
Why this score
Operating growth, Large positive market reaction, Positive market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
High · 61/100
30-day weight
18.6% of the score · 21.6d old
Duplicates
1 consolidated
#11—Not directional
EquitymasterDirect company coverageScored from headline

MARKSANS PHARMA. Share Price Today Up 10%

Published
12 Aug 2026 07:09
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 21.7d old
Duplicates
1 consolidated
#1281Tone
CNBC TV18Direct company coverageScored from headline

Marksans Pharma Q1 Results: Shares jump 11% after profit nearly triples, margin expands

Published
12 Aug 2026 07:00
News subject
Earnings
Why this score
Margin expansion, Large positive market reaction, Positive market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
High · 62/100
30-day weight
18.9% of the score · 21.7d old
Duplicates
1 consolidated
#1373Tone
EquitypanditDirect company coverageScored from headline

Marksans Pharma Hits 52-Week High, Shares Jump 14%

Published
12 Aug 2026 07:00
News subject
Market update
Why this score
Large positive market reaction, Positive market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 46/100
30-day weight
<0.1% of the score · 21.7d old
Duplicates
1 consolidated
#1466Tone
Business StandardDirect company coverageScored from headline

Marksans Pharma consolidated net profit rises 169.50% in the June 2026 quarter

Published
12 Aug 2026 07:00
News subject
Earnings
Why this score
Operating growth
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 43/100
30-day weight
10.1% of the score · 21.7d old
Duplicates
1 consolidated
#1657Tone
scanx.tradeDirect company coverageScored from headline

Marksans Pharma posts record EBITDA of ₹213 cr in Q1FY27

Published
12 Aug 2026 07:00
News subject
Market update
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Low · 28/100
30-day weight
<0.1% of the score · 21.7d old
Duplicates
1 consolidated
#17—Not directional
scanx.tradeDirect company coverageScored from headlineSource lookup

Marksans Pharma publishes notice for 34th annual general meeting

Published
06 Aug 2026 06:54
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 27.7d old
Duplicates
1 consolidated
#18—Not directional
scanx.tradeDirect company coverageScored from headlineSource lookup

Marksans Pharma submits FY26 BRSR with 100% export focus

Published
05 Aug 2026 21:54
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 28.0d old
Duplicates
1 consolidated

Earlier company news

MARKSANS news archive

14 older headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Older news is kept in the archive

There are 14 older MARKSANS headlines. Open one page at a time when you need them.

Open older archive

Provider matches checked

Provider mentions not used in the score

1 not scored

A news provider linked these stories to MARKSANS, but the headline and available text are not mainly about Marksans Pharma Limited. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

Provider mentions are kept separate

Open the list to see which provider matches were checked and left out of MARKSANS sentiment.

Open provider mentions

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context